Investor Presentaiton
TWO SIGNIFICANT DISEASES
Diabetic Macular Edema (DME)
Q Chronic complication and leading cause of
blindness in diabetic patients
QU.S. diabetic population of 32 million in 2021
growing at ~11% per year
Q Approximately 1.7 million patients in Alimera's
major markets in 20201
Q Approximately 4.1% of all diabetics develop
clinically significant macular edema
alimera
Non-Infectious Uveitis Affecting the
Posterior Segment
Q Chronic inflammatory conditions that can lead
to pain, visual impairment and vision loss; often
affects working age adults
Q Over 500,000 patients in U.S. with non-
infectious uveitis affecting the posterior
segment²
Between 40-50% of uveitis cases affect the
posterior segment³
NOTES:
1.
Data from IDF Atlas 10th Edition and Global Prevalence of Diabetic Retinopathy and Projection of Burden through 2045 Systematic Review
and Meta-analysis 2021. Major markets include U.S., France, Germany, Italy, UK, Portugal, and Spain
2. https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5904090/#:~:text=From%20the%205106%20interviewed %20US,20%20to%2069%20years%20
old and https://retinatoday.com/articles/2016-july-aug/the-burden-of-noninfectious-uveitis-of-the-posterior-segment-a-review
3. https://retinatoday.com/articles/2016-july-aug/the-burden-of-noninfectious-uveitis-of-the-posterior-segment-a-review
Nasdaq: ALIM
6View entire presentation